Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗

November 03, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.

Via Benzinga

Merus Announces Financial Results for the Third Quarter and Provides Business Update

November 03, 2022

From Merus N.V.

Via GlobeNewswire

What 4 Analyst Ratings Have To Say About Merus ↗

October 13, 2022

Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About Merus ↗

October 13, 2022

Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings:

Via Benzinga

Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday ↗

October 27, 2022

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the...

Via Benzinga

Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

October 26, 2022

From Merus N.V.

Via GlobeNewswire

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus ↗

January 26, 2022

Incyte Corporation (NASDAQ: INCY) is

Via Benzinga

Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session ↗

October 26, 2022

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate...

Via Benzinga

Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday ↗

October 13, 2022

Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at...

Via Benzinga

Analyst Casts Doubts On Merus' Lung Candidate Safety Profile ↗

October 12, 2022

Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small...

Via Benzinga

Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

October 12, 2022

From Merus N.V.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 ↗

August 02, 2022

Upgrades

Via Benzinga

Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 14, 2022

On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier.

Via Investor's Business Daily

Needham Says Merus' ASCO Update On Zeno 'Positive' ↗

June 06, 2022

Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer.

Via Benzinga

70 Biggest Movers From Friday ↗

May 31, 2022

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q2 ↗

April 21, 2022

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗

February 10, 2022

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,...

Via Benzinga

Promising Developments in Breast Cancer Treatments Ahead in 2022

January 12, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...

Via FinancialNewsMedia

Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings ↗

December 10, 2021

Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗

November 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Notable Merus Insider Makes $31M Sale ↗

October 11, 2021

Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and...

Via Benzinga

Topics Regulatory Compliance

45 Biggest Movers From Yesterday ↗

October 08, 2021

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher ↗

October 07, 2021

Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has...

Via Benzinga

Topics Stocks

Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors ↗

October 07, 2021

Merus is flirting with a buy point on its strong, early-stage cancer test results.

Via Investor's Business Daily

Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide ↗

October 07, 2021

Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Merus Stock Is Flying Higher Today ↗

October 07, 2021

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

Via The Motley Fool

Why Are Merus Shares Soaring Thursday? ↗

October 07, 2021

Merus N.V. (NASDAQ: MRUS) has presented data on MCLA-158 and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views ↗

October 07, 2021

Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also rose, gaining 1.45% to 4,426.68. The U.S....

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.